Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
March 29, 2023 16:50 ET
|
Aerovate Therapeutics, Inc.
Progress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Expanded intellectual property portfolio with four issued patents in 2022 ...
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
March 02, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
January 23, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
November 17, 2022 07:45 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
November 14, 2022 07:45 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
October 18, 2022 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today presents the design of IMPAHCT (Inhaled iMatinib for Pulmonary Arterial Hypertension Clinical...
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
August 15, 2022 07:50 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 02, 2022 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
May 16, 2022 17:15 ET
|
Aerovate Therapeutics, Inc.
AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high...
Aerovate Therapeutics Announces First Quarter 2022 Financial Results
May 16, 2022 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...